

# Luigino Calzetta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7398938/publications.pdf>

Version: 2024-02-01

285  
papers

6,829  
citations

61857

43  
h-index

102304

66  
g-index

290  
all docs

290  
docs citations

290  
times ranked

5774  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacology and Therapeutics of Bronchodilators. <i>Pharmacological Reviews</i> , 2012, 64, 450-504.	7.1	379
2	A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. <i>Chest</i> , 2016, 149, 1181-1196.	0.4	206
3	$\beta_2$ -adrenoceptor agonists: current and future direction. <i>British Journal of Pharmacology</i> , 2011, 163, 4-17.	2.7	142
4	Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , 2015, 24, 451-461.	3.0	140
5	Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , 2017, 124, 6-14.	1.3	131
6	Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. <i>Lancet Respiratory Medicine</i> , 2013, 1, 714-727.	5.2	121
7	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 40, 95-103.	1.1	112
8	TNF- $\alpha$ inhibitors in asthma and COPD: We must not throw the baby out with the bath water. <i>Pulmonary Pharmacology and Therapeutics</i> , 2010, 23, 121-128.	1.1	108
9	Pharmacology and Therapeutics of Bronchodilators Revisited. <i>Pharmacological Reviews</i> , 2020, 72, 218-252.	7.1	104
10	Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2018, 52, 1801586.	3.1	101
11	Asthma and comorbid medical illness. <i>European Respiratory Journal</i> , 2011, 38, 42-49.	3.1	98
12	Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. <i>European Journal of Pharmacology</i> , 2015, 761, 168-173.	1.7	97
13	Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. <i>Respiratory Medicine</i> , 2012, 106, 249-256.	1.3	89
14	Emerging anti-inflammatory strategies for COPD. <i>European Respiratory Journal</i> , 2012, 40, 724-741.	3.1	84
15	Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 414-423.	1.3	80
16	Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. <i>European Journal of Pharmacology</i> , 2014, 745, 135-143.	1.7	80
17	Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 552-563.	0.7	77
18	Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 175-181.	0.7	73

#	ARTICLE	IF	CITATIONS
19	Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , 2016, 17, 70.	1.4	71
20	High Glucose Enhances Responsiveness of Human Airways Smooth Muscle via the Rho/ROCK Pathway. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 47, 509-516.	1.4	66
21	Adding a LAMA to ICS/LABA Therapy. <i>Chest</i> , 2019, 155, 758-770.	0.4	65
22	Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , 2020, 6, 47-66.	1.1	63
23	Thunderstorm-related asthma: Not only grass pollen and spores. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 537-538.	1.5	60
24	Oxidation pathway and exacerbations in COPD: the role of NAC. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 89-97.	1.0	60
25	Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. <i>Respiratory Research</i> , 2017, 18, 26.	1.4	60
26	Canakinumab for the treatment of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 15-27.	1.1	57
27	Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. <i>Current Opinion in Pharmacology</i> , 2018, 40, 95-103.	1.7	57
28	The prevalence of asthma and COPD in Italy: A practice-based study. <i>Respiratory Medicine</i> , 2011, 105, 386-391.	1.3	55
29	Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , 2015, 109, 1305-1311.	1.3	54
30	Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 804-814.	1.4	54
31	Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 148-158.	1.1	54
32	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. <i>Respiratory Medicine</i> , 2017, 129, 189-198.	1.3	54
33	Comorbidities of asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 36-41.	1.2	53
34	Brain natriuretic peptide: Much more than a biomarker. <i>International Journal of Cardiology</i> , 2016, 221, 1031-1038.	0.8	51
35	TSLP Inhibitors for Asthma: Current Status and Future Prospects. <i>Drugs</i> , 2020, 80, 449-458.	4.9	51
36	LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. <i>European Respiratory Review</i> , 2017, 26, 160043.	3.0	50

#	ARTICLE	IF	CITATIONS
37	Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. <i>British Journal of Pharmacology</i> , 2011, 163, 1740-1754.	2.7	49
38	Focus on Cat Allergen (Fel d 1): Immunological and Aerodynamic Characteristics, Modality of Airway Sensitization and Avoidance Strategies. <i>International Archives of Allergy and Immunology</i> , 2003, 132, 1-12.	0.9	48
39	Role of Sensitization to Mammalian Serum Albumin in Allergic Disease. <i>Current Allergy and Asthma Reports</i> , 2011, 11, 421-426.	2.4	48
40	Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1133-1146.	1.0	47
41	Interaction between corticosteroids and muscarinic antagonists in human airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 36, 1-9.	1.1	47
42	Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 2020, 177, 1150-1163.	2.7	47
43	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. <i>Vaccines</i> , 2021, 9, 227.	2.1	47
44	Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 15-23.	1.1	46
45	Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 940-951.	4.0	46
46	SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000625.	3.1	46
47	Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. <i>Respiratory Research</i> , 2019, 20, 104.	1.4	45
48	Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 452-463.	4.0	42
49	Are there pulmonary sequelae in patients recovering from COVID-19?. <i>Respiratory Research</i> , 2020, 21, 286.	1.4	42
50	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. <i>European Respiratory Review</i> , 2018, 27, 180010.	3.0	41
51	Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011, 24, 221-226.	1.1	40
52	Diabetes mellitus among outpatients with COPD attending a university hospital. <i>Acta Diabetologica</i> , 2014, 51, 933-940.	1.2	40
53	The impact of comorbidities on severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 47-55.	1.2	40
54	The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 733-744.	2.5	39

#	ARTICLE	IF	CITATIONS
55	Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 48, 88-96.	1.1	39
56	Control of asthma for reducing the risk of bronchospasm in asthmatics undergoing general anesthesia and/or intravascular administration of radiographic contrast media. <i>Current Medical Research and Opinion</i> , 2009, 25, 1621-1630.	0.9	38
57	Pharmacological Characterization of Adenosine Receptors on Isolated Human Bronchi. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 1222-1231.	1.4	38
58	The Challenges of Precision Medicine in COPD. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 345-355.	1.6	37
59	Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011, 20, 291-298.	2.5	36
60	Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , 2016, 76, 1257-1270.	4.9	36
61	Protein Prenylation Contributes to the Effects of LPS on EFS-Induced Responses in Human Isolated Bronchi. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 704-710.	1.4	35
62	The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 325-331.	1.1	35
63	The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. <i>International Journal of COPD</i> , 2017, Volume 12, 3469-3485.	0.9	35
64	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. <i>Respiratory Medicine</i> , 2019, 154, 86-92.	1.3	35
65	Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. <i>Respiratory Medicine</i> , 2019, 153, 3-13.	1.3	35
66	LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. <i>International Journal of COPD</i> , 2018, Volume 13, 3115-3130.	0.9	32
67	Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101841.	1.1	32
68	Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. <i>European Journal of Pharmacology</i> , 2015, 761, 383-390.	1.7	31
69	Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. <i>European Respiratory Journal</i> , 2021, 58, 2004233.	3.1	31
70	Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1007-1013.	1.5	30
71	Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. <i>Respiratory Research</i> , 2018, 19, 65.	1.4	30
72	Multifaceted activity of N-acetylcysteine in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 693-708.	1.0	30

#	ARTICLE	IF	CITATIONS
73	Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A <sub>2</sub> for the Treatment of Asthma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 656-665.	1.3	29
74	β <sub>2</sub> -Adrenoceptor Modulation in Chronic Obstructive Pulmonary Disease: Present and Future Perspectives. <i>Drugs</i> , 2013, 73, 1653-1663.	4.9	29
75	Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. <i>Drugs</i> , 2017, 77, 721-732.	4.9	29
76	Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD. <i>Current Opinion in Pharmacology</i> , 2018, 40, 39-45.	1.7	29
77	Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 143-152.	1.0	29
78	Effects of chronic treatment with the new ultra-long-acting β <sub>2</sub> -adrenoceptor agonist indacaterol alone or in combination with the β <sub>1</sub> -adrenoceptor blocker metoprolol on cardiac remodelling. <i>British Journal of Pharmacology</i> , 2015, 172, 3627-3637.	2.7	28
79	Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. <i>Drug Safety</i> , 2016, 39, 501-508.	1.4	28
80	Pharmacological treatments in asthma-affected horses: A pairwise and network meta-analysis. <i>Equine Veterinary Journal</i> , 2017, 49, 710-717.	0.9	28
81	Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. <i>European Journal of Pharmacology</i> , 2017, 812, 147-154.	1.7	28
82	Human Hair: An Unexpected Source of Cat Allergen Exposure. <i>International Archives of Allergy and Immunology</i> , 2005, 137, 141-144.	0.9	27
83	Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 478-482.	1.1	27
84	Treatment of COPD: moving beyond the lungs. <i>Current Opinion in Pharmacology</i> , 2012, 12, 315-322.	1.7	27
85	Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 561-568.	1.0	27
86	Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?. <i>Drugs</i> , 2014, 74, 1983-1992.	4.9	26
87	Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. <i>Respiratory Medicine</i> , 2016, 117, 150-153.	1.3	26
88	Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 261-264.	1.0	26
89	Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 827-833.	1.9	26
90	Immune sensitization of equine bronchus: glutathione, IL-1β expression and tissue responsiveness. <i>Respiratory Research</i> , 2005, 6, 104.	1.4	25

#	ARTICLE	IF	CITATIONS
91	Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia. <i>European Journal of Pharmacology</i> , 2015, 765, 463-471.	1.7	25
92	Tiotropium formulations and safety: a network meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 17-30.	1.0	25
93	Anaphylaxis caused by skin prick testing with aeroallergens: Case report and evaluation of the risk in Italian allergy services. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 1410-1412.	1.5	24
94	How does race/ethnicity influence pharmacological response to asthma therapies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 435-446.	1.5	24
95	Long-acting muscarinic antagonists and small airways in asthma: Which link?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1990-2001.	2.7	24
96	Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. <i>Vaccines</i> , 2021, 9, 341.	2.1	24
97	Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. <i>Respiratory Medicine</i> , 2020, 171, 106114.	1.3	23
98	Advances with glucocorticoids in the treatment of asthma: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2305-2316.	0.9	23
99	Emerging drugs for chronic obstructive pulmonary disease. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 61-82.	1.0	22
100	Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit. <i>Respiratory Medicine</i> , 2013, 107, 1417-1422.	1.3	22
101	The effect of indacaterol during an acute exacerbation of COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 630-634.	1.1	21
102	Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. <i>Respiratory Medicine</i> , 2015, 109, 1019-1025.	1.3	21
103	Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and) Tj ETQq1 1 0.784314rgBT /Ovarlock 1	1.1	21
104	Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 56, 39-50.	1.1	21
105	Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. <i>Drugs</i> , 2020, 80, 1799-1809.	4.9	21
106	Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom. <i>Journal of Clinical Medicine</i> , 2021, 10, 1607.	1.0	21
107	Effects of neuraminidase on equine isolated bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 624-629.	1.1	20
108	Brain Natriuretic Peptide Protects against Hyperresponsiveness of Human Asthmatic Airway Smooth Muscle via an Epithelial Cell-Dependent Mechanism. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 50, 493-501.	1.4	20



#	ARTICLE	IF	CITATIONS
109	Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. <i>Life Sciences</i> , 2015, 131, 44-50.	2.0	20
110	Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 48, 185-194.	1.1	20
111	N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 1-8.	2.5	20
112	Washing the clothes of cat owners is a simple method to prevent cat allergen dispersal. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 143-144.	1.5	19
113	Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 573-581.	1.9	18
114	Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. <i>Advances in Therapy</i> , 2019, 36, 3291-3298.	1.3	18
115	Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. <i>Pharmacological Research</i> , 2021, 172, 105801.	3.1	18
116	The cardiovascular risk of tiotropium: is it real?. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 783-792.	1.0	17
117	Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 526-532.	0.7	17
118	Impact of doxofylline in COPD: A pairwise meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 51, 1-9.	1.1	17
119	Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab. <i>British Journal of Pharmacology</i> , 2020, 177, 4750-4765.	2.7	17
120	Prospects for severe asthma treatment. <i>Current Opinion in Pharmacology</i> , 2021, 56, 52-60.	1.7	17
121	The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. <i>International Journal of COPD</i> , 2021, Volume 16, 257-279.	0.9	17
122	Umeclidinium for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 665-671.	1.0	16
123	The risk of sensitization to furry animals in patients already sensitized to cat/dog: An in vitro evaluation using molecular-based allergy diagnostics. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1664-1666.	1.5	16
124	Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101828.	1.1	16
125	Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101855.	1.1	16
126	Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 233-253.	1.5	16



#	ARTICLE	IF	CITATIONS
127	Sex differences in COPD management. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 323-332.	1.3	16
128	Bronchial asthma. <i>Current Opinion in Anaesthesiology</i> , 2012, 25, 30-37.	0.9	15
129	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 129-137.	1.5	15
130	Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. <i>Clinical and Molecular Allergy</i> , 2018, 16, 3.	0.8	15
131	What could be the role of molecular-based allergy diagnostics in detecting the risk of developing allergic sensitization to furry animals?. <i>European Annals of Allergy and Clinical Immunology</i> , 2015, 47, 163-7.	0.4	15
132	Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC <sub>2</sub> receptors. <i>British Journal of Pharmacology</i> , 2010, 161, 1329-1342.	2.7	14
133	Exploring the neural mechanisms of finasteride: a proteomic analysis in the nucleus accumbens. <i>Psychoneuroendocrinology</i> , 2016, 74, 387-396.	1.3	14
134	Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 28-37.	1.1	13
135	The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 589-596.	1.0	13
136	Enfentrine (RPL554): an inhaled "bifunctional"™ dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. <i>Pharmaceutical Patent Analyst</i> , 2018, 7, 249-257.	0.4	13
137	Monoclonal antibodies in severe asthma: is it worth it?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 517-520.	1.5	13
138	The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review. <i>Biomedicines</i> , 2021, 9, 1281.	1.4	13
139	Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 737-750.	0.9	13
140	Efficacy of dry-cleaning in removing Fel d 1 allergen from wool fabric exposed to cats. <i>Annals of Allergy, Asthma and Immunology</i> , 2002, 88, 301-305.	0.5	12
141	Is cat-keeping the main determinant of new-onset adulthood cat sensitization?. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1689-1690.	1.5	12
142	A 6MWT index to predict O <sub>2</sub> flow correcting exercise induced SpO <sub>2</sub> desaturation in ILD. <i>Respiratory Medicine</i> , 2013, 107, 2014-2021.	1.3	12
143	Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine. <i>EBioMedicine</i> , 2017, 19, 14-15.	2.7	12
144	Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. <i>European Journal of Pharmacology</i> , 2018, 832, 114-119.	1.7	12

#	ARTICLE	IF	CITATIONS
145	Bronchodilators in subjects with asthma-related comorbidities. <i>Respiratory Medicine</i> , 2019, 151, 43-48.	1.3	12
146	Anthelmintic medicinal plants in veterinary ethnopharmacology: A network meta-analysis following the PRISMA-P and PROSPERO recommendations. <i>Heliyon</i> , 2020, 6, e03256.	1.4	12
147	&lt;p&gt;Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease&lt;/p&gt;. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 559-574.	1.5	12
148	Anaphylaxis and intimate behaviour. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 350-355.	1.1	11
149	Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis. <i>Equine Veterinary Journal</i> , 2018, 50, 594-601.	0.9	11
150	Long-Acting $\beta$ 2-Agonists in Asthma: Enantioselective Safety Studies are Needed. <i>Drug Safety</i> , 2018, 41, 441-449.	1.4	11
151	Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. <i>World Allergy Organization Journal</i> , 2019, 12, 100081.	1.6	11
152	Coronavirus Disease 2019: COSeSco – A Risk Assessment Score to Predict the Risk of Pulmonary Sequelae in COVID-19 Patients. <i>Respiration</i> , 2022, 101, 272-280.	1.2	11
153	The 5T approach in asthma: Triple Therapy Targeting Treatable Traits. <i>Respiratory Medicine</i> , 2022, 200, 106915.	1.3	11
154	A Novel and Effective Balanced Intravenous-Inhalant Anaesthetic Protocol in Swine by Using Unrestricted Drugs. <i>Experimental Animals</i> , 2014, 63, 423-433.	0.7	10
155	Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 51-54.	1.1	10
156	Non respiratory symptoms in asthma as possible predictors of exacerbations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 798-800.e2.	2.0	10
157	Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. <i>Multidisciplinary Respiratory Medicine</i> , 2019, 14, 25.	0.6	10
158	Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 977-990.	1.3	10
159	Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 611-620.	0.9	10
160	Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis. <i>Monaldi Archives for Chest Disease</i> , 2022, , .	0.3	10
161	Dual bronchodilation for the treatment of COPD: From bench to bedside. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3657-3673.	1.1	10
162	Direct and Indirect Exposure to Horse: Risk for Sensitization and Asthma. <i>Current Allergy and Asthma Reports</i> , 2012, 12, 429-437.	2.4	9

#	ARTICLE	IF	CITATIONS
163	Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 641-647.	0.7	9
164	Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 239-245.	1.5	9
165	Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2018, 41, 546-554.	0.6	9
166	Immunoprophylaxis pharmacotherapy against canine leishmaniosis: A systematic review and meta-analysis on the efficacy of vaccines approved in European Union. <i>Vaccine</i> , 2020, 38, 6695-6703.	1.7	9
167	Drug interaction and chronic obstructive respiratory disorders. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100009.	1.7	9
168	Step-up and step-down approaches in the treatment of asthma. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1159-1168.	1.0	9
169	Detection of Small Airway Dysfunction in Asymptomatic Smokers with Preserved Spirometry: The Value of the Impulse Oscillometry System. <i>International Journal of COPD</i> , 2021, Volume 16, 2585-2590.	0.9	9
170	SMART for the treatment of asthma: A network meta-analysis of real-world evidence. <i>Respiratory Medicine</i> , 2021, 188, 106611.	1.3	9
171	Beyond Dual Bronchodilation – Triple Therapy, When and Why. <i>International Journal of COPD</i> , 2022, Volume 17, 165-180.	0.9	9
172	Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies. <i>European Annals of Allergy and Clinical Immunology</i> , 2016, 48, 61-4.	0.4	9
173	Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 595-607.	2.5	8
174	The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. <i>BioMed Research International</i> , 2016, 2016, 1-7.	0.9	8
175	Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting $\beta_2$ -Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. <i>Pulmonary Therapy</i> , 2019, 5, 117-126.	1.1	8
176	Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2178-2180.	1.2	8
177	Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 59-70.	1.0	8
178	Classes of drugs that target the cellular components of inflammation under clinical development for COPD. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1015-1027.	1.3	8
179	The future of inhalation therapy in chronic obstructive pulmonary disease. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100092.	1.7	8
180	The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. <i>European Respiratory Review</i> , 2022, 31, 210196.	3.0	8

#	ARTICLE	IF	CITATIONS
181	Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 156-157.	1.1	7
182	Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life?. <i>Allergologia Et Immunopathologia</i> , 2016, 44, 387-388.	1.0	7
183	Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 791-793.	2.0	7
184	Onset of action of budesonide/formoterol Spiromax <sup>®</sup> compared with budesonide/formoterol Turbuhaler <sup>®</sup> in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 39, 48-53.	1.1	7
185	Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 813-822.	1.5	7
186	Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 88-94.	1.1	7
187	Is ICS+LAMA an alternative option to treat patients with COPD?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 316-317.	5.2	7
188	Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018, 15, 310-311.	0.7	7
189	A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101883.	1.1	7
190	The role of triple therapy in the management of COPD. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 865-874.	1.3	7
191	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 891-906.	2.4	7
192	The COPD assessment test and the modified Medical Research Council scale are not equivalent when related to the maximal exercise capacity in COPD patients. <i>Pulmonology</i> , 2023, 29, 194-199.	1.0	7
193	Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 69, 102050.	1.1	7
194	Small airways in asthma: from bench-to-bedside. <i>Minerva Medica</i> , 2022, 113, .	0.3	7
195	Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. <i>Cells</i> , 2022, 11, 1797.	1.8	7
196	Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 0,9		
197	Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "œreal life"?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 535.	2.0	6
198	Pharmacogenetic and pharmacogenomic considerations of asthma treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1159-1167.	1.5	6

#	ARTICLE	IF	CITATIONS
199	A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety, 2018, 17, 509-517.	1.0	6
200	Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy?. Human Vaccines and Immunotherapeutics, 2018, 14, 1438-1441.	1.4	6
201	Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. Journal of Allergy and Clinical Immunology, 2019, 143, 1657-1658.	1.5	6
202	&lt;p&gt;Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy&lt;/p&gt;. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 261-271.	0.4	6
203	Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. International Journal of Molecular Sciences, 2021, 22, 7132.	1.8	6
204	Ventilation Heterogeneity in Asthma and COPD: The Value of the Poorly Communicating Fraction as the Ratio of Total Lung Capacity to Alveolar Volume. Respiration, 2021, 100, 404-410.	1.2	6
205	Benralizumab for the treatment of asthma. Drugs of Today, 2017, 53, 633.	0.7	6
206	Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in "cereal life"? European Annals of Allergy and Clinical Immunology, 2018, 50, 283.	0.4	6
207	Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma. Pulmonary Pharmacology and Therapeutics, 2022, 73-74, 102125.	1.1	6
208	Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile. Journal of Asthma and Allergy, 2022, Volume 15, 565-577.	1.5	6
209	Can the levels of Can f 1 in indoor environments be evaluated without considering passive transport of allergen indoors?. Journal of Allergy and Clinical Immunology, 2013, 131, 1258-1259.	1.5	5
210	The clinical use of regenerative therapy in COPD. International Journal of COPD, 2014, 9, 1389.	0.9	5
211	Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection?. Journal of Allergy and Clinical Immunology, 2016, 137, 1621-1622.	1.5	5
212	Assessing the viability of long-acting $\beta_2$ -agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 129-136.	1.5	5
213	What Could the Role of Can f 5 Allergen Be in Dog- Sensitized Patients in "Real Life"? Journal of Investigational Allergology and Clinical Immunology, 2017, 27, 397-398.	0.6	5
214	Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). Expert Opinion on Investigational Drugs, 2020, 29, 723-738.	1.9	5
215	A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2399-2401.	2.0	5
216	Pharmacological interactions: Synergism, or not synergism, that is the question. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100046.	1.7	5

#	ARTICLE	IF	CITATIONS
217	Face masks during COVID-19 pandemic lockdown and self-reported seasonal allergic rhinitis symptoms. <i>Rhinology</i> , 2021, 59, 0-0.	0.7	5
218	Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1473-1481.	1.0	5
219	Acclidinium/formoterol fixed-dose combination for the treatment of chronic obstructive pulmonary disease. <i>Drugs of Today</i> , 2015, 51, 97.	0.7	5
220	Sensitization to rodents (mouse/rat) in urban atopic populations without occupational exposure living in Campania district (Southern Italy): a multicenter study. <i>Multidisciplinary Respiratory Medicine</i> , 2013, 8, 30.	0.6	4
221	Partial nephrectomy using radiofrequency incremental bipolar generator with multi electrode probe: experimental study in bench pig kidneys. <i>BMC Urology</i> , 2014, 14, 7.	0.6	4
222	How many systemic reactions to skin prick tests could be preventable in defined conditions?. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 174.	0.5	4
223	Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 833-835.	0.9	4
224	Clinical efficacy of bronchodilators in equine asthma: Looking for minimal important difference. <i>Equine Veterinary Journal</i> , 2020, 52, 305-313.	0.9	4
225	Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100010.	1.7	4
226	Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 579-581.	1.0	4
227	Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. <i>Respiratory Medicine</i> , 2021, 189, 106639.	1.3	4
228	Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. <i>US Respiratory &amp; Pulmonary Diseases</i> , 2020, 5, 18.	0.2	4
229	Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies. <i>Journal of Experimental Pharmacology</i> , 2022, Volume 14, 1-5.	1.5	4
230	Sensitization to horse allergens without apparent exposure to horse. Report of two cases. <i>European Annals of Allergy and Clinical Immunology</i> , 2005, 37, 350-2.	0.4	4
231	Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 917-927.	0.9	4
232	An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1205-1216.	0.9	4
233	Major rabbit allergen Ory c 3: What could be its possible role as a sensitizing agent in real life?. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 283-284.	1.5	3
234	Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Immunology: in Practice</i> , 2017, 5, 873.	2.0	3



#	ARTICLE	IF	CITATIONS
235	Geographical characteristics influencing the risk of poisoning in pet dogs: Results of a large population-based epidemiological study in Italy. <i>Veterinary Journal</i> , 2018, 235, 63-69.	0.6	3
236	Isolated airways in equine respiratory pharmacology: They never lie. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101849.	1.1	3
237	Comparative studies of dual bronchodilation in COPD. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, .	0.3	3
238	Mortality in ETHOS: A Question of "Power". <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 926-927.	2.5	3
239	Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 357-365.	1.0	3
240	Editorial overview: Respiratory: Pulmonary pharmacology "The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives. <i>Current Opinion in Pharmacology</i> , 2021, 60, 54-58.	1.7	3
241	Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study. <i>European Annals of Allergy and Clinical Immunology</i> , 2019, 51, 44.	0.4	3
242	10.1538/expanim.63.423. <i>Experimental Animals</i> , 2014, 99999, 99999999-99999999.	0.7	3
243	Dog allergen immunotherapy and allergy to furry animals. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 590.	0.5	2
244	Olodaterol + tiotropium bromide for the treatment of COPD. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 379-386.	1.0	2
245	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 20-26.	1.1	2
246	Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 621-635.	1.0	2
247	Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020, 17, 215-223.	0.7	2
248	Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	2
249	As needed therapies in mild to severe asthma: a systematic review and network meta-analysis. , 2020, , .		2
250	Incidence of intentional poisoning of dogs in the Abruzzo region of Italy. <i>Veterinary and Human Toxicology</i> , 2002, 44, 111-3.	0.3	2
251	An unusual case of occupational asthma in a part time magician. He has got an allergy surprise from his top hat!. <i>European Annals of Allergy and Clinical Immunology</i> , 2014, 46, 178-80.	0.4	2
252	Clinical manifestations of a new alpha1 antitrypsin genetic variant: <sc> <i>Q0parma</i> </sc>. <i>Respirology Case Reports</i> , 2022, 10, e0936.	0.3	2



#	ARTICLE	IF	CITATIONS
253	Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models. <i>Heliyon</i> , 2022, 8, e09760.	1.4	2
254	Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2016, 26, 403-405.	0.6	1
255	Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens. <i>Upsala Journal of Medical Sciences</i> , 2016, 121, 196-197.	0.4	1
256	Gastroesophageal reflux and <scp>COPD</scp> exacerbations: Is cholinergicâ€mediated oesophagoâ€bronchial reflex a possible link?. <i>Respirology</i> , 2016, 21, 1496-1497.	1.3	1
257	Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma?. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 19-20.	1.0	1
258	Anxiety and asthma in youth. Is a stressâ€induced increased cholinergic tone the possible link?. <i>Pediatric Pulmonology</i> , 2018, 53, 128-129.	1.0	1
259	Occupational exposure to furry animals and asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 512-513.	0.5	1
260	Response. <i>Chest</i> , 2019, 155, 1079-1080.	0.4	1
261	Current long-acting muscarinic antagonists for the treatment of asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-15.	0.9	1
262	Protein tyrosin kinase and KCa++ channel: two faces of the same coin in LABA/LAMA synergy. , 2017, , .		1
263	Clinical synergism of LABA/LAMA combinations in COPD patients. , 2017, , .		1
264	Cardiovascular disease in COPD. , 2020, , 47-65.		1
265	Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy). <i>European Annals of Allergy and Clinical Immunology</i> , 2020, 52, 230.	0.4	1
266	Use of face masks and allergic rhinitis from ragweed: Why mention only total pollen count and not air pollution levels?. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 886-888.	1.5	1
267	The interplay between diabetes mellitus and chronic obstructive pulmonary disease. <i>Minerva Medica</i> , 2023, 114, .	0.3	1
268	Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience. <i>European Annals of Allergy and Clinical Immunology</i> , 2017, 49, 92-96.	0.4	1
269	Bronchial asthma: an update. <i>Minerva Medica</i> , 2022, 113, .	0.3	1
270	A pilot survey on the quality of life in respiratory rehabilitation carried out in COPD patients with severe respiratory failure: preliminary data of a novel Inpatient Respiratory Rehabilitation Questionnaire (IRRQ). <i>Multidisciplinary Respiratory Medicine</i> , 2012, 7, 46.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals?. <i>Journal of Occupational Health</i> , 2017, 59, 310-311.	1.0	0
272	Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1808-1809.	2.0	0
273	Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1093-1094.	2.0	0
274	Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?. <i>International Archives of Allergy and Immunology</i> , 2019, 180, 142-143.	0.9	0
275	Can placebo challenge test (inducing a "nocebo effect") be a suitable model to assess stress-induced bronchial obstruction? Suggestions from the multidisciplinary Working Groups "Stress-Asthma" and "AALITO Regione Campania". <i>European Annals of Allergy and Clinical Immunology</i> , 2021, 53, 284.	0.4	0
276	Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 943-945.	0.9	0
277	Occupational allergy to horse allergens: More than exposure to horses!. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2016, 29, 721-723.	0.6	0
278	Critical interpretation of pairwise and network meta-analysis of randomized respiratory clinical trials. <i>AboutOpen</i> , 2019, 6, 55-61.	0.2	0
279	Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy? Possible Explanations. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 472-473.	0.6	0
280	Anxiety depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link. <i>European Annals of Allergy and Clinical Immunology</i> , 2020, 52, 190-192.	0.4	0
281	Excellence paves the way with current research in pharmacology and drug discovery. <i>Current Research in Pharmacology and Drug Discovery</i> , 2020, 1, iv.	1.7	0
282	Prescribing the right therapy for the treatment of chronic cough: a critical focus on current and investigational options. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , 1-4.	0.9	0
283	Use of face masks and allergic nasal symptoms: Why not mention pollen count and air pollution data?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, , 103363.	0.6	0
284	A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 269-283.	1.3	0
285	Systematic Literature Review of Treatments Used for Refractory or Unexplained Chronic Cough in Adults. , 2022, , .		0